Suppression of corticosteroid-induced ocular hypertension in sheep by anecortave

Archives of Ophthalmology

Volumn 128, Issue 3, 2010, Pages 338-343

  Candia, Oscar A ^a   Gerometta, Rosana ^b   Millar, J Cameron ^c   Podos, Steven M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

^c ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; PREDNISOLONE ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR OUTFLOW; ARTICLE; DRUG EFFECT; FEMALE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; SHEEP;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; AQUEOUS HUMOR; DISEASE MODELS, ANIMAL; FEMALE; GLUCOCORTICOIDS; INJECTIONS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PREDNISOLONE; PREGNADIENEDIOLS; SHEEP; TONOMETRY, OCULAR;

EID: 77749319635     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.387     Document Type: Article

References (36)

1. Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol. 2007;52(suppl 1):S26-S34.
2. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs. 1997;6(12):1867-1877.
3. Russell, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration: a review of clinical outcomes. Surv Ophthalmol. 2007;52(suppl 1):S79-S90.
4. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs. 2007;21(4):245-257.
5. Robin AL, Suan EP, Sjaarda RN, Callanan DG, Defaller J; Alcon Anecortave Acetate for IOP Research Team. Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma. Arch Ophthalmol. 2009;127(2):173-178.
6. Robin AL, Clark AF, Covert DW, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147(1):45-50, e2.
7. Gerometta R, Podos SM, Danias J, Candia OA. Steroid-induced ocular hypertension in normal sheep. Invest Ophthalmol Vis Sci. 2009;50(2):669-673.
8. Sears ML. Outflow resistance of the rabbit eye, technique and effects of acetazolamide: determination by constant rate anterior chamber infusion in vivo. Arch Ophthalmol. 1960;64:823-838.
9. Bárány EH. Simultaneous measurement of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthalmol. 1964;3:135-143.
10. Millar JC, Pang I-H, Clark AF. Aqueous humor dynamics in the mouse by constant flow infusion [ARVO abstract 354]. Invest Ophthalmol Vis Sci. 2008.
11. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005;112(1):139-143.
12. McLean J. Use of ACTH and cortisone. Trans Am Ophthalmol Soc. 1950;48:293-296.
13. Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163-167.
14. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006;20(4):407-416.
15. Pang IH, Moll H, McLaughlin MA, et al. Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A (sodium ferri ethylenediaminetetraacetate) . Exp Eye Res. 2001;73(6):815-825.
16. Neufeld AH, Dueker DK, Vegge T, Sears ML. Adenosine 3-′,5′-- monophosphate increases the outflow of aqueous humor from the rabbit eye. Invest Ophthalmol. 1975;14(1):40-42.
17. Krupin T, Oestrich CJ, Bass J, Podos SM, Becker B. Acidosis, alkalosis, and aqueous humor dynamics in rabbits. Invest Ophthalmol Vis Sci. 1977;16(11):997-1001.
18. Krupin T, Becker B, Podos SM. Topical vanadate lowers intraocular pressure in rabbits. Invest Ophthalmol Vis Sci. 1980;19(11):1360-1363.
19. Oksala O, Heino P, Uusitalo H, Palkama A. Effect of intracameral and intravitreal injection of calcitonin gene-related peptide on the intraocular pressure and outflow facility of aqueous humor in the rabbit. Exp Eye Res. 1998;67(4):411-415.
20. Puras G, Santafe J, Segarra J, Garrido M, Melena J. A comparative study of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in ocular normotensive and alpha-chymotrypsin-induced ocular hypertensive rabbits. Graefes Arch Clin Exp Ophthalmol. 2007;245(10):1559-1567.
21. Toris CB, Zhan GL, McLaughlin MA. Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. J Ocul Pharmacol Ther. 2003;19(5):397-404.
22. Kaufman PL. Pressure-dependent outflow. In: Ritch R, ed. The Glaucomas. St Louis, MO: Mosby; 1996:307-335.
23. Clark AF, Brotchie D, Read AT, et al. Dexamethasone alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue. Cell Motil Cytoskeleton. 2005;60(2):83-95.
24. Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1994;35(1):281-294.
25. Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci. 1990;31(12):2568-2571.
26. Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783-793.
27. Yue BY. The extracellular matrix and its modulation in the trabecular meshwork. Surv Ophthalmol. 1996;40(5):379-390.
28. Matsumoto Y, Johnson DH. Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ. Invest Ophthalmol Vis Sci. 1997;38(9):1902-1907.
29. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18(5):629-667.
30. Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84(2):275-284.
31. Underwood JL, Murphy CG, Chen J, et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277(2, pt 1):C330-C342.
32. Xiong X, Miao J, Xi Z, Zhang H, Han B, Hu Y. Regulatory effect of dexamethasone on aquaporin-1 expression in cultured bovine trabecular meshwork cells. J Huazhong Univ Sci Technolog Med Sci. 2005;25(6):735-737.
33. Rozsa FW, Reed DM, Scott KM, et al. Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis. 2006;12:125-141.
34. Gerometta R, Spiga MG, Candia OA, Borrás T. Treatment of steroid-induced ocular hypertension by inducible gene transfer of MMP1 in sheep [ARVO abstract 5722]. Invest Ophthalmol Vis Sci. 2009.
35. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999;117(4):498-503.
36. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2):267-285.